Drug combo may slow kidney failure in rare alport syndrome
NCT ID NCT06499948
First seen Apr 25, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This study tests whether two common kidney drugs, dapagliflozin and spironolactone, can reduce protein leakage in the urine of adults with Alport syndrome, a genetic kidney disease. About 34 participants will try each drug alone and then together, with the goal of slowing kidney damage. The trial aims to find a better way to delay the need for dialysis or transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPORT SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fundeni Clinical Institute
Bucharest, Sector 2, 020021, Romania
Conditions
Explore the condition pages connected to this study.